Eka Melson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eka Melson has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Punith Kempegowda
Department of Applied Health Sciences, School of Health Sciences, College of Medicine and Health University of Birmingham Birmingham UK
15 shared publications Dengyi Zhou
London North West University Healthcare NHS Trust London UK
6 shared publicationsWentin Chen
Medical School, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
6 shared publicationsMeri Davitadze
Clinic NeoLab Tbilisi Georgia
5 shared publicationsEmma Ooi
RCSI & UCD Malaysia Campus, Georgetown, Pulau Pinang, Malaysia
4 shared publicationsLucretia Thomas
College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
4 shared publications
Latest Publications
- Open Access
Optimisation and Validation of a UHPLC-MS/MS Assay Using Timed Post-Column Ammonium Fluoride Infusion for Sensitive Serum Steroids Quantitation
Steroid metabolomics has potential for identifying biomarkers and improving disease diagnosis. However, poor ionisation efficiency and low circulating concentrations of some steroids limit the broader clinical applications. Here, we developed a ultra-high-performance liquid chromatography – tandem mass spectrometry (UHPLC-MS/MS) assay for quantitation of 18 steroids in serum encompassing the mineralocorticoid, glucocorticoid and androgen biosynthesis pathways, including both classic and 11-oxygenated androgens. Steroid extraction from 100 μL of serum was performed using supported liquid extraction with ethyl acetate elution. Ionisation efficiency of steroids was investigated using formic acid in the mobile phase and post-column infusion of ammonium fluoride. Ammonium fluoride enhanced the signal intensity of 3-keto-Δ4 steroids up to ninefold, however A-ring reduced steroids exhibited greater ionisation with formic acid. Thus, to optimise sensitivity, a timed post-column infusion of 2 mmol/L ammonium fluoride was employed during chromatographic separation. The lower limits of quantitation ranged from 0.04 to 2.1 nmol/L. Accuracy ranged from 82 to 113% and intra- and inter-assay imprecision was <10% and <13%, respectively. The assay was applied to analyse morning serum steroid concentrations in healthy individuals (55 women, 44 men; age-matched). Serum progesterone, 11-deoxycorticosterone, dehydroepiandrosterone and androstenedione were significantly higher in women; in contrast, testosterone and 5α-dihydrotestosterone were higher in men. In summary, we have successfully developed and validated a UHPLC-MS/MS assay for multi-steroid profiling ad applied it to healthy individuals of both sexes.
Open AccessOptimisation and Validation of a UHPLC-MS/MS Assay Using Timed Post-Column Ammonium Fluoride Infusion for Sensitive Serum Steroids Quantitation
Steroid metabolomics has potential for identifying biomarkers and improving disease diagnosis. However, poor ionisation efficiency and low circulating concentrations of some steroids limit the broader clinical applications. Here, we developed a ultra-high-performance liquid chromatography – tandem mass spectrometry (UHPLC-MS/MS) assay for quantitation of 18 steroids in serum encompassing the mineralocorticoid, glucocorticoid and androgen biosynthesis pathways, including both classic and 11-oxygenated androgens. Steroid extraction from 100 μL of serum was performed using supported liquid extraction with ethyl acetate elution. Ionisation efficiency of steroids was investigated using formic acid in the mobile phase and post-column infusion of ammonium fluoride. Ammonium fluoride enhanced the signal intensity of 3-keto-Δ4 steroids up to ninefold, however A-ring reduced steroids exhibited greater ionisation with formic acid. Thus, to optimise sensitivity, a timed post-column infusion of 2 mmol/L ammonium fluoride was employed during chromatographic separation. The lower limits of quantitation ranged from 0.04 to 2.1 nmol/L. Accuracy ranged from 82 to 113% and intra- and inter-assay imprecision was <10% and <13%, respectively. The assay was applied to analyse morning serum steroid concentrations in healthy individuals (55 women, 44 men; age-matched). Serum progesterone, 11-deoxycorticosterone, dehydroepiandrosterone and androstenedione were significantly higher in women; in contrast, testosterone and 5α-dihydrotestosterone were higher in men. In summary, we have successfully developed and validated a UHPLC-MS/MS assay for multi-steroid profiling ad applied it to healthy individuals of both sexes.
- Open Access
Inhibition of the androgen-activating enzyme AKR1C3 selectively decreases systemic and intra-adipose 11-oxygenated androgens in women
Androgen excess drives metabolic and reproductive complications in polycystic ovary syndrome (PCOS), affecting 10-15% of women globally. Aldo-keto reductase 1C3 (AKR1C3) converts inactive precursors from both the classic and the recently identified 11-oxygenated androgen pathways, generating testosterone and 11-ketotestosterone, respectively, which exert comparable androgen receptor activation. Both circulate in similar concentrations in premenopausal women while 11-ketotestosterone is predominant after menopause and in PCOS. Here, we show that adipocytes are a major site of AKR1C3 and androgen receptor expression, with increased expression in women and individuals with obesity. Using human female adipose tissue explants, we find a much higher activation of 11-oxygenated over classic androgens, observing a decrease in 11-oxygenated but not classic androgen activation by AKR1C3 inhibition. Correspondingly, we demonstrate that AKR1C3 inhibitor treatment in premenopausal women selectively disrupts the activation of 11-oxygenated androgens. Pharmacological targeting of AKR1C3 provides a novel strategy to alleviate systemic and intra-adipose 11-oxygenated androgen excess. One Sentence Summary: Inhibition of the androgen-activating enzyme AKR1C3 results in a major decrease in 11-oxygenated but not classic androgens in women.
Open AccessInhibition of the androgen-activating enzyme AKR1C3 selectively decreases systemic and intra-adipose 11-oxygenated androgens in women
Androgen excess drives metabolic and reproductive complications in polycystic ovary syndrome (PCOS), affecting 10-15% of women globally. Aldo-keto reductase 1C3 (AKR1C3) converts inactive precursors from both the classic and the recently identified 11-oxygenated androgen pathways, generating testosterone and 11-ketotestosterone, respectively, which exert comparable androgen receptor activation. Both circulate in similar concentrations in premenopausal women while 11-ketotestosterone is predominant after menopause and in PCOS. Here, we show that adipocytes are a major site of AKR1C3 and androgen receptor expression, with increased expression in women and individuals with obesity. Using human female adipose tissue explants, we find a much higher activation of 11-oxygenated over classic androgens, observing a decrease in 11-oxygenated but not classic androgen activation by AKR1C3 inhibition. Correspondingly, we demonstrate that AKR1C3 inhibitor treatment in premenopausal women selectively disrupts the activation of 11-oxygenated androgens. Pharmacological targeting of AKR1C3 provides a novel strategy to alleviate systemic and intra-adipose 11-oxygenated androgen excess. One Sentence Summary: Inhibition of the androgen-activating enzyme AKR1C3 results in a major decrease in 11-oxygenated but not classic androgens in women.
- Open Access
- 7 July 2025
- Published by BMJ in BMJ Open Quality
- Vol. 14 (3) , e003223
Improving the rates of inpatient HbA 1c assessment and medication deintensification in people with diabetes and frailty
Background: Intensive glucose management in people with diabetes and frailty presents significant risk which outweighs potential benefit. Hospital admission presents an opportunity for interventions that may reduce the impact of overtreatment in people with diabetes and frailty. Our previous study has shown low rates of glycated haemoglobin(HbA 1c ) assessment and inpatient medication deintensification in people with diabetes and frailty. Methods: We conducted a three-intervention quality improvement programme and studied the effectiveness of the interventions aiming to improve the inpatient HbA 1c assessment and management of inpatients with diabetes and frailty. A baseline assessment was conducted prior to cycles 1 and 2, with another audit conducted post-cycles 1 and 2. A further audit was then carried out with another audit post-cycle 3. Interventions: Interventions 1 and 2 involved publishing an infographic to aid assessment and medication deintensification in patients with diabetes and frailty, followed by spreading awareness among resident doctors of the baseline audit results and the infographic via email and WhatsApp groups. Intervention 3 involved allocating ‘Diafrailty Champion’ the medical wards to help improve the assessment and management of patients with diabetes and frailty. Results: A total of 291 patients with diabetes and moderate–severe frailty were included in our audits (96 patients in baseline audit, 102 post-cycles 1 and 2 audit, 92 post-cycle 3 ‘Diafrailty Champion’ audit). Improvements were observed for the rates of HbA 1c assessment and deintensification in the post-interventions 1 and 2 audit, and these persisted following the introduction of ‘Diafrailty Champion’. Conclusions: Interventions that included raising awareness of the inpatient assessment and management of people with diabetes and frailty were successful in improving inpatient HbA 1c assessment and deintensification rates. The improved HbA 1c assessment and deintensification rates persist following the engagement of a resident doctor ‘Diafrailty Champion’.
- 7 July 2025
- Published by BMJ in BMJ Open Quality
- Vol. 14 (3) , e003223
Open AccessImproving the rates of inpatient HbA 1c assessment and medication deintensification in people with diabetes and frailty
Background: Intensive glucose management in people with diabetes and frailty presents significant risk which outweighs potential benefit. Hospital admission presents an opportunity for interventions that may reduce the impact of overtreatment in people with diabetes and frailty. Our previous study has shown low rates of glycated haemoglobin(HbA 1c ) assessment and inpatient medication deintensification in people with diabetes and frailty. Methods: We conducted a three-intervention quality improvement programme and studied the effectiveness of the interventions aiming to improve the inpatient HbA 1c assessment and management of inpatients with diabetes and frailty. A baseline assessment was conducted prior to cycles 1 and 2, with another audit conducted post-cycles 1 and 2. A further audit was then carried out with another audit post-cycle 3. Interventions: Interventions 1 and 2 involved publishing an infographic to aid assessment and medication deintensification in patients with diabetes and frailty, followed by spreading awareness among resident doctors of the baseline audit results and the infographic via email and WhatsApp groups. Intervention 3 involved allocating ‘Diafrailty Champion’ the medical wards to help improve the assessment and management of patients with diabetes and frailty. Results: A total of 291 patients with diabetes and moderate–severe frailty were included in our audits (96 patients in baseline audit, 102 post-cycles 1 and 2 audit, 92 post-cycle 3 ‘Diafrailty Champion’ audit). Improvements were observed for the rates of HbA 1c assessment and deintensification in the post-interventions 1 and 2 audit, and these persisted following the introduction of ‘Diafrailty Champion’. Conclusions: Interventions that included raising awareness of the inpatient assessment and management of people with diabetes and frailty were successful in improving inpatient HbA 1c assessment and deintensification rates. The improved HbA 1c assessment and deintensification rates persist following the engagement of a resident doctor ‘Diafrailty Champion’.
- Open Access
- 17 March 2025
- Published by Wiley in The Clinical Teacher
- Vol. 22 (3) , e70070
SIMBA: Online Simulation for Teaching Medical Cases to Preclinical Students—A Pilot Study
Background: Medical education employs diverse teaching strategies, including blending lecture‐based learning, small‐group teaching (SGT) and, increasingly, simulation‐based learning. Nonetheless, limitations in clinical application and participation persist. Simulation via Instant Messaging for Bedside Application (SIMBA) complements these methods by simulating real‐world clinical scenarios. This pilot study compares SIMBA's effectiveness with SGT in endocrine topics for medical and pharmacy students. Methods: The SIMBA for students model was developed using Kern's six‐step framework. SIMBA sessions, facilitated by trained moderators and senior experts, simulated outpatient consultations via WhatsApp. The study included SIMBA and SGT sessions from October 2020 to March 2022. Teaching effectiveness was assessed through postsession surveys and multiple‐choice questions (MCQs). The study compared the MCQ scores and student satisfaction of SIMBA, SGT and combined SIMBA + SGT cohorts. Results: One hundred thirty (103 medical and 27 pharmacy) students participated in 14 SIMBA sessions, and 150 students responded to the post‐SGT survey, with 38 attending both. Median MCQ scores were higher post‐SIMBA (75.0%) compared with post‐SGT (60.0%) ( p < 0.0001). No significant difference was observed between SIMBA and SIMBA + SGT scores or SGT and SIMBA + SGT scores. SIMBA sessions were perceived as enjoyable (89.2%), intelligible (90.8%), engaging (81.5%), promoted new knowledge (90.0%) and enhanced comprehension (93.9%). 83.1% of students desired SIMBA to complement SGT. Conclusions: SIMBA demonstrated superior knowledge gain and student satisfaction compared to SGT. Its familiar technology and interactive format suit modern learning, offering a standardised and equitable experience. Integrating SIMBA into the curriculum could help overcome teaching limitations and better prepare students for clinical practice.
- 17 March 2025
- Published by Wiley in The Clinical Teacher
- Vol. 22 (3) , e70070
Open AccessSIMBA: Online Simulation for Teaching Medical Cases to Preclinical Students—A Pilot Study
Background: Medical education employs diverse teaching strategies, including blending lecture‐based learning, small‐group teaching (SGT) and, increasingly, simulation‐based learning. Nonetheless, limitations in clinical application and participation persist. Simulation via Instant Messaging for Bedside Application (SIMBA) complements these methods by simulating real‐world clinical scenarios. This pilot study compares SIMBA's effectiveness with SGT in endocrine topics for medical and pharmacy students. Methods: The SIMBA for students model was developed using Kern's six‐step framework. SIMBA sessions, facilitated by trained moderators and senior experts, simulated outpatient consultations via WhatsApp. The study included SIMBA and SGT sessions from October 2020 to March 2022. Teaching effectiveness was assessed through postsession surveys and multiple‐choice questions (MCQs). The study compared the MCQ scores and student satisfaction of SIMBA, SGT and combined SIMBA + SGT cohorts. Results: One hundred thirty (103 medical and 27 pharmacy) students participated in 14 SIMBA sessions, and 150 students responded to the post‐SGT survey, with 38 attending both. Median MCQ scores were higher post‐SIMBA (75.0%) compared with post‐SGT (60.0%) ( p < 0.0001). No significant difference was observed between SIMBA and SIMBA + SGT scores or SGT and SIMBA + SGT scores. SIMBA sessions were perceived as enjoyable (89.2%), intelligible (90.8%), engaging (81.5%), promoted new knowledge (90.0%) and enhanced comprehension (93.9%). 83.1% of students desired SIMBA to complement SGT. Conclusions: SIMBA demonstrated superior knowledge gain and student satisfaction compared to SGT. Its familiar technology and interactive format suit modern learning, offering a standardised and equitable experience. Integrating SIMBA into the curriculum could help overcome teaching limitations and better prepare students for clinical practice.
- Open Access
- 2 May 2024
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 25 (7) , 801-818
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have changed the landscape of type 2 diabetes (T2D) management due to their cardio-renal benefits, their glucose-lowering efficacy and weight loss (WL) maintenance. However, the response to GLP-1 RA monotherapy is heterogeneous. Additionally, the majority of GLP-1 RAs are injectable treatments. Oral GLP-1 RAs and injectable combinations of GLP-1 with other entero-pancreatic hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon and amylin) are under development for T2D and obesity management. Herein, we review the data on (i) oral GLP-1 RAs (oral semaglutide 25/50 mg and orforglipron) and (ii) dual/triple agonists (tirzepatide, cagrilintide 2.4 mg/semaglutide 2.4 mg, survodutide, mazdutide, retatrutide) that have recently completed phase 3 trials for T2D or are currently in phase 3 clinical trials. Tirzepatide is the first approved dual agonist (GLP-1/GIP) for T2D and obesity management. We are in a new era in T2D management where entero-pancreatic hormone-based treatments can result in ≥15% WL and euglycemia for many people with T2D. Multiple molecules with different mechanisms of action are under development for T2D, obesity and other metabolic complications. Data on their cardio-renal benefits, long-term efficacy and safety as well as their cost-effectiveness will better inform their position in treatment algorithms.
- 2 May 2024
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 25 (7) , 801-818
Open AccessOral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have changed the landscape of type 2 diabetes (T2D) management due to their cardio-renal benefits, their glucose-lowering efficacy and weight loss (WL) maintenance. However, the response to GLP-1 RA monotherapy is heterogeneous. Additionally, the majority of GLP-1 RAs are injectable treatments. Oral GLP-1 RAs and injectable combinations of GLP-1 with other entero-pancreatic hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon and amylin) are under development for T2D and obesity management. Herein, we review the data on (i) oral GLP-1 RAs (oral semaglutide 25/50 mg and orforglipron) and (ii) dual/triple agonists (tirzepatide, cagrilintide 2.4 mg/semaglutide 2.4 mg, survodutide, mazdutide, retatrutide) that have recently completed phase 3 trials for T2D or are currently in phase 3 clinical trials. Tirzepatide is the first approved dual agonist (GLP-1/GIP) for T2D and obesity management. We are in a new era in T2D management where entero-pancreatic hormone-based treatments can result in ≥15% WL and euglycemia for many people with T2D. Multiple molecules with different mechanisms of action are under development for T2D, obesity and other metabolic complications. Data on their cardio-renal benefits, long-term efficacy and safety as well as their cost-effectiveness will better inform their position in treatment algorithms.
- Top Cited PapersOpen Access
- 1 February 2024
- Published by Springer Nature in International Journal of Obesity
- Vol. 49 (3) , 433-451
What is the pipeline for future medications for obesity?
Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15–17% mean weight loss (WL) with evidence of cardioprotection. Oral GLP-1 RA are also under development and early data shows similar WL efficacy to semaglutide 2.4 mg. Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA. Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials. Other combinations of entero-pancreatic hormones including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA) have also progressed to phase 3 trials as obesity treatments and early data suggests that may lead to even greater WL than tirzepatide. Additionally, agents with different mechanisms of action to entero-pancreatic hormones (e.g. bimagrumab) may improve the body composition during WL and are in early phase clinical trials. We are in a new era for obesity pharmacotherapy where combinations of entero-pancreatic hormones approach the WL achieved with bariatric surgery. In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based treatments and we consider the clinical implications and challenges that the new era in obesity management may bring.
- 1 February 2024
- Published by Springer Nature in International Journal of Obesity
- Vol. 49 (3) , 433-451
Top Cited PapersOpen AccessWhat is the pipeline for future medications for obesity?
Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15–17% mean weight loss (WL) with evidence of cardioprotection. Oral GLP-1 RA are also under development and early data shows similar WL efficacy to semaglutide 2.4 mg. Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA. Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials. Other combinations of entero-pancreatic hormones including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA) have also progressed to phase 3 trials as obesity treatments and early data suggests that may lead to even greater WL than tirzepatide. Additionally, agents with different mechanisms of action to entero-pancreatic hormones (e.g. bimagrumab) may improve the body composition during WL and are in early phase clinical trials. We are in a new era for obesity pharmacotherapy where combinations of entero-pancreatic hormones approach the WL achieved with bariatric surgery. In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based treatments and we consider the clinical implications and challenges that the new era in obesity management may bring.
- 30 October 2023
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 99 (6) , e20-e21
Mentorship Without Borders: The Transformative Impact on Inclusivity, International Collaborations, and Cross-Cultural Competence
- 30 October 2023
- Published by Oxford University Press (OUP) in Academic Medicine
- Vol. 99 (6) , e20-e21
Mentorship Without Borders: The Transformative Impact on Inclusivity, International Collaborations, and Cross-Cultural Competence
- Open Access
Factors associated with therapeutic inertia in individuals with type 2 diabetes mellitus started on basal insulin
Aim: In this study we aim to identify the risk factors for treatment inertia in patients with type 2 diabetes mellitus (T2DM) who have been recently started on basal insulin (BI). Methods: Using UK CPRD GOLD, we identified adults with T2DM with suboptimal glycaemia (HbA1c within 12 months of BI ≥7% (≥53 mmol/mol)). We used multivariable Cox regression model to describe the association between patient characteristics and the time to treatment intensification. Results: A total of 12,556 patients were analysed. Compared to individuals aged <65 years, those aged ≥65 years had lower risk of treatment intensification (HR: 0.69; 95% CI: 0.64-0.73). Other risk factors included being female (0.93, 0.89-0.99), longer T2DM duration (0.99, 0.98-0.99), living in the most deprived areas (0.90, 0.83-0.98), being a current smoker (0.91, 0.84-0.98), having one (0.91, 0.85- 0.97) or more than one comorbidity (0.88, 0.82-0.94), and patients who were on metformin (0.71, 0.63-0.80), or 2nd generation sulphonylureas (0.85; 0.79-0.92) or DPP4 inhibitors (0.87, 0.82-0.93) compared to those who were not. Conclusion: Therapeutic inertia still remains a major barrier, with multiple factors associated with delay in intensification. Interventions to overcome therapeutic inertia need to be implemented at both patient and health care professional level.
Open AccessFactors associated with therapeutic inertia in individuals with type 2 diabetes mellitus started on basal insulin
Aim: In this study we aim to identify the risk factors for treatment inertia in patients with type 2 diabetes mellitus (T2DM) who have been recently started on basal insulin (BI). Methods: Using UK CPRD GOLD, we identified adults with T2DM with suboptimal glycaemia (HbA1c within 12 months of BI ≥7% (≥53 mmol/mol)). We used multivariable Cox regression model to describe the association between patient characteristics and the time to treatment intensification. Results: A total of 12,556 patients were analysed. Compared to individuals aged <65 years, those aged ≥65 years had lower risk of treatment intensification (HR: 0.69; 95% CI: 0.64-0.73). Other risk factors included being female (0.93, 0.89-0.99), longer T2DM duration (0.99, 0.98-0.99), living in the most deprived areas (0.90, 0.83-0.98), being a current smoker (0.91, 0.84-0.98), having one (0.91, 0.85- 0.97) or more than one comorbidity (0.88, 0.82-0.94), and patients who were on metformin (0.71, 0.63-0.80), or 2nd generation sulphonylureas (0.85; 0.79-0.92) or DPP4 inhibitors (0.87, 0.82-0.93) compared to those who were not. Conclusion: Therapeutic inertia still remains a major barrier, with multiple factors associated with delay in intensification. Interventions to overcome therapeutic inertia need to be implemented at both patient and health care professional level.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Simulation via Instant Messaging - Birmingham Advance helps to narrow the gap of knowledge and expectations between clinicians and women with polycystic ovary syndrome: A SIMBA-PCOS mixed-method study
Introduction: Educational interventions for healthcare professionals (HCPs) in diabetes and endocrinology often limits patient and public involvement (PPI). We studied the effectiveness of Simulation via Instant Messaging-Birmingham Advance (SIMBA) as a tool to improve knowledge about polycystic ovary syndrome (PCOS) in HCP and women with PCOS. Additionally, we aimed to identify and reduce gaps in knowledge and expectations between HCP and women living with PCOS. Methods: HCP and women with PCOS underwent simulation-based and workshop-based learning respectively on four PCOS case scenarios. These were followed by a debriefing session chaired by experts in PCOS, where women with PCOS also shared their experiences of PCOS. Data on confidence and expectations regarding PCOS were collected pre-and post-SIMBA. Wilcoxon Signed-Rank test was used to compare changes in confidence pre-and post-simulation. Thematic induction was used to identify areas of gaps between expectation and care from questionnaires and discussion session involving HCP and women with PCOS. Results: 25 HCP and 15 women with PCOS completed our questionnaires. HCPs reported increased confidence to manage PCOS cases (simulated:+41.0%, PPP=0.0141) and 17.7% (P=0.0002) increase in PPI participants’ confidence in HCPs to diagnose and manage PCOS-related issues respectively. Thematic analysis revealed four areas of gaps between expectation and care—delays in diagnosis, lack of information provided regarding further symptoms development and long-term complications, symptom-focused care instead of a holistic approach, and lack of information provided for the treatment they receive. Conclusion: SIMBA-PCOS is an effective tool for both women with PCOS and HCPs to enhance their confidence and understand each other’s perspectives. It also helped reduce gaps in knowledge and expectations between women with PCOS and HCPs.
- 27 October 2022
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 86
Simulation via Instant Messaging - Birmingham Advance helps to narrow the gap of knowledge and expectations between clinicians and women with polycystic ovary syndrome: A SIMBA-PCOS mixed-method study
Introduction: Educational interventions for healthcare professionals (HCPs) in diabetes and endocrinology often limits patient and public involvement (PPI). We studied the effectiveness of Simulation via Instant Messaging-Birmingham Advance (SIMBA) as a tool to improve knowledge about polycystic ovary syndrome (PCOS) in HCP and women with PCOS. Additionally, we aimed to identify and reduce gaps in knowledge and expectations between HCP and women living with PCOS. Methods: HCP and women with PCOS underwent simulation-based and workshop-based learning respectively on four PCOS case scenarios. These were followed by a debriefing session chaired by experts in PCOS, where women with PCOS also shared their experiences of PCOS. Data on confidence and expectations regarding PCOS were collected pre-and post-SIMBA. Wilcoxon Signed-Rank test was used to compare changes in confidence pre-and post-simulation. Thematic induction was used to identify areas of gaps between expectation and care from questionnaires and discussion session involving HCP and women with PCOS. Results: 25 HCP and 15 women with PCOS completed our questionnaires. HCPs reported increased confidence to manage PCOS cases (simulated:+41.0%, PPP=0.0141) and 17.7% (P=0.0002) increase in PPI participants’ confidence in HCPs to diagnose and manage PCOS-related issues respectively. Thematic analysis revealed four areas of gaps between expectation and care—delays in diagnosis, lack of information provided regarding further symptoms development and long-term complications, symptom-focused care instead of a holistic approach, and lack of information provided for the treatment they receive. Conclusion: SIMBA-PCOS is an effective tool for both women with PCOS and HCPs to enhance their confidence and understand each other’s perspectives. It also helped reduce gaps in knowledge and expectations between women with PCOS and HCPs.
- Open Access
- 31 October 2021
- Published by BMJ
- Vol. 5 (Suppl 1) , A20.3-A20
55 Simulation via instant messaging – birmingham advance (SIMBA) effectively develops leadership and interpersonal skills in medical students and junior doctors
Background Simulation via Instant Messaging - Birmingham Advance (SIMBA) is a simulation-based learning model increasing clinicians’ confidence in managing various clinical scenarios. The international team delivering SIMBA sessions is composed of medical students and junior doctors. Executing these sessions requires team members to lead peers, communicate with senior doctors, and delegate roles to ensure completion of case preparation, moderator training, and advertisement. Objectives We studied whether SIMBA affects the leadership and teamwork skills of medical students and junior doctors. Methods 33 medical students and junior doctors were included in the study based on their experience in leadership roles in SIMBA. Participants completed open-ended questions, Leadership Trait Questionnaire (LTQ) and Teamwork Skills Questionnaire (TSQ) twice; first as they would respond at present, and second as they would have responded prior to joining SIMBA. Pre- and post-SIMBA involvement scores were compared for each of the measured traits from both questionnaires and analysed using Wilcoxon signed-rank test. Common themes were identified and inductive thematic analysis was performed. Results On average, each participant had spent six months in SIMBA. Post-SIMBA evaluation showed significant improvement in 9/14 LTQ traits (pConclusions Leadership and teamwork skills are vital for medical students and junior doctors. Our study proves that involvement with a novel platform such as SIMBA is effective in fostering these skills at an early career stage.
- 31 October 2021
- Published by BMJ
- Vol. 5 (Suppl 1) , A20.3-A20
Open Access55 Simulation via instant messaging – birmingham advance (SIMBA) effectively develops leadership and interpersonal skills in medical students and junior doctors
Background Simulation via Instant Messaging - Birmingham Advance (SIMBA) is a simulation-based learning model increasing clinicians’ confidence in managing various clinical scenarios. The international team delivering SIMBA sessions is composed of medical students and junior doctors. Executing these sessions requires team members to lead peers, communicate with senior doctors, and delegate roles to ensure completion of case preparation, moderator training, and advertisement. Objectives We studied whether SIMBA affects the leadership and teamwork skills of medical students and junior doctors. Methods 33 medical students and junior doctors were included in the study based on their experience in leadership roles in SIMBA. Participants completed open-ended questions, Leadership Trait Questionnaire (LTQ) and Teamwork Skills Questionnaire (TSQ) twice; first as they would respond at present, and second as they would have responded prior to joining SIMBA. Pre- and post-SIMBA involvement scores were compared for each of the measured traits from both questionnaires and analysed using Wilcoxon signed-rank test. Common themes were identified and inductive thematic analysis was performed. Results On average, each participant had spent six months in SIMBA. Post-SIMBA evaluation showed significant improvement in 9/14 LTQ traits (pConclusions Leadership and teamwork skills are vital for medical students and junior doctors. Our study proves that involvement with a novel platform such as SIMBA is effective in fostering these skills at an early career stage.